Nusinersen Therapy
Nusinersen Therapy is a pharmacotherapeutic intervention classified as an antisense oligonucleotide-based treatment that selectively modulates SMN2 gene splicing to increase production of functional survival motor neuron protein in patients with spinal muscular atrophy.
246
Publications
16.5K
Citations
1.8K
Authors
561
Institutions
Publications per year
2017–2026
243
246
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Richard S. Finkel, Eugenio Mercuri, Basil T. Darras et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Eugenio Mercuri, Basil T. Darras, Claudia A. Chiriboga et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text
Medicine, Neurology, Neuroscience +17
Darryl C. De Vivo, Enrico Bertini, Kathryn J. Swoboda et al. · Neuromuscular Disorders · 2019 · 626 citations · Full text
Medicine, Neurology, Pediatrics +10
1–5 of 246
1.8K
19
h-index
19
h-index
19
h-index
16
h-index
16
h-index
1–5 of 1.8K
561

University of Freiburg
Freiburg im Breisgau, Germany
18 h-index
81 publications
10.4K citations
Bambino Gesù Children's Hospital
Rome, Italy
17 h-index
49 publications
3.1K citations

Biogen (United States)
Cambridge, United States
17 h-index
102 publications
26K citations

Columbia University Irving Medical Center
New York, United States
16 h-index
30 publications
10.1K citations
Centro Clinico Nemo
Milan, Italy
16 h-index
109 publications
5.7K citations

University of Milan
Milan, Italy
15 h-index
55 publications
2.9K citations

Università Cattolica del Sacro Cuore
Milan, Italy
15 h-index
55 publications
2.5K citations
Medizinische Hochschule Hannover
Hanover, Germany
15 h-index
94 publications
4.3K citations
1–8 of 561
14 publications · 1K citations
13
h-index
13 publications · 642 citations
13
h-index
10 publications · 259 citations
11
h-index
10 publications · 1.2K citations
11
h-index
10 publications · 608 citations
11
h-index
1–5